Literature DB >> 8611467

NA-phenotype-dependent differences in neutrophil Fc gamma RIIIb expression cause differences in plasma levels of soluble Fc gamma RIII.

H R Koene1, M de Haas, M Kleijer, D Roos, A E von dem Borne.   

Abstract

Soluble Fc gamma RIII in plasma is primarily derived from neutrophils and is a measure of the total body neutrophil mass. We have developed a new, sensitive 'sandwich' ELISA to measure soluble Fc gamma RIII in plasma and released Fc gamma RIII in cell supernatants. Both sFc gamma RIIIa, derived from NK cells and sFc gamma RIIIb, derived from neutrophils are detected in the assay. However, plasma analysis of Fc gamma RIIIB gene-deficient donors suggested that sFc gamma RIIIa contributes only marginally to the total amount measured in healthy individuals. Furthermore, we observed that plasma of homozygous NA1-positive donors contained lower amounts of sFc gamma RIII than plasma of homozygous NA2-positive donors. Heterozygous donors were found to have intermediate levels of sFc gamma RIII in their plasma. Hemizygous Fc gamma RIIIB gene-deficient donors were found to have half the amount of sFc gamma RIII in their plasma compared to donors with two Fc gamma RIIIB alleles. These NA phenotype-dependent differences in plasma sFc gamma RIII could not be contributed to either an assay artefact or NA-dependent differences in shedding of Fc gamma RIIIb upon neutrophil activation. Calibration curves constructed with plasma of homozygous donors did nor reveal NA-dependent differences in antibody affinity. Measurement of released Fc gamma RIIIb in supernatants of neutrophils stimulated with PMA, and inhibition of this signal with human IgG revealed no NA-dependent differences. However, NA-dependent differences in neutrophil Fc gamma RIIIb expression were present, comparable to the differences found in plasma levels of sFc gamma RIII. Differences in the amounts of released Fc gamma RIII in supernatants of NA-typed apoptotic neutrophils were similar to initial differences in Fc gamma RIIIb expression, again being lower in NA1-positive than in heterozygous and NA2-positive donors. In conclusion, NA-dependent differences in plasma levels of soluble Fc gamma RIII seem to be caused by differences in expression of the receptor on the neutrophil membrane.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611467     DOI: 10.1046/j.1365-2141.1996.4971038.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy humans.

Authors:  P E Dekkers; T ten Hove; F N Lauw; H R Koene; P Lumley; S J van Deventer; T van der Poll
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  Levels of soluble Fc gammaRIII correlate with disease severity in sepsis.

Authors:  A C Muller Kobold; J G Zijlstra; H R Koene; M de Haas; C G Kallenberg; J W Tervaert
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

3.  Different proteolytic mechanisms involved in Fc gamma RIIIb shedding from human neutrophils.

Authors:  P J Middelhoven; J D Van Buul; P L Hordijk; D Roos
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

4.  An integrated approach for measuring copy number variation at the FCGR3 (CD16) locus.

Authors:  Edward J Hollox; Jan-Christoph Detering; Tushna Dehnugara
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

5.  Measurement of soluble Fcgamma receptor type IIIa derived from macrophages in plasma: increase in patients with rheumatoid arthritis.

Authors:  M Masuda; T Morimoto; S Kobatake; N Nishimura; K Nakamoto; X H Dong; Y Komiyama; R Ogawa; H Takahashi
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

6.  Soluble FcgammaRIIIa(Mphi) levels in plasma correlate with carotid maximum intima-media thickness (IMT) in subjects undergoing an annual medical checkup.

Authors:  Midori Masuda; Katsuya Amano; Shi Yan Hong; Noriko Nishimura; Masayoshi Fukui; Masamichi Yoshika; Yutaka Komiyama; Hiroya Masaki; Toshiji Iwasaka; Hakuo Takahashi
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.